$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
NEW YORK, May 11, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD, Inc. ("TherapeuticsMD") (NYSEMKT:TXMD) securities between July 7, 2016 and April 9, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-004HR NDA.
If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
